• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Sebetralstat improves symptom relief in acute hereditary angioedema attacks

byJessie WillisandTeddy Guo
February 22, 2023
in Chronic Disease, Emergency, Rheumatology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. An oral dose of sebetralstat increased the time to conventional treatment use and lead to faster symptom relief in acute hereditary angioedema attacks compared to control.

2. Sebetralstat was well tolerated and was demonstrated to rapidly reduce activity of plasma kallikrein.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Hereditary angioedema is a rare disease that causes episodic attacks of tissue swelling. Current treatments include on-demand and prophylactic medications, but these are parenterally administered. This phase 2 drug study aims to evaluate the use of an oral plasma kallikrein inhibitor, sebetralstat, for the on-demand treatment of angioedema attacks. This study had two parts. Part 1 was a safety, pharmacokinetics, and pharmacodynamics assessment where all enrolled patients received the study drug of 600 mg oral sebetralstat after the screening. The drug was found to be well tolerated and led to rapid suppression of plasma kallikrein activity. In Part 2, the participants were randomized to either sequence 1 (sebetralstat, then placebo) or sequence 2 (placebo, then sebetralstat). In summary, the time to conventional treatment usage within 12 h of the study drug administration was significantly longer with sebetralstat versus placebo. In addition, symptom relief was much faster with the use of sebetralstat versus placebo. There were no serious adverse events. Limitations of this study include the within-participant dependence of endpoints due to the crossover. Nevertheless, this study shows promising early results for the safety and efficacy of sebetralstat. A larger confirmatory phase 3 trial is currently underway.

Click to read the study in The Lancet

Relevant Reading: Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema

In-Depth [randomized controlled trial]: This international phase 2 drug trial evaluated the use of a novel oral plasma kallikrein inhibitor, sebetralstat, for the on-demand treatment of acute flares of hereditary angioedema. Eligible participants were aged over 18 years old and had a confirmed diagnosis of hereditary angioedema type 1 or 2 with three or more attacks in the past 93 days. Life-threatening attacks, such as laryngeal or facial attacks, were also excluded due to safety. The mean age of the enrolled participants (n=68) was 38.3 years and 54% were female. In part 1, all participants were given sebetralstat as a single oral dose within 28 days of their screening visit. In part 2, participants were randomized 1:1 to either sequence 1 (600 mg sebetralstat, then placebo) or sequence 2 (placebo, then 600 mg sebetralstat). For example, in sequence 1, patients were to self-administer 600 mg sebetralstat after their first attack and placebo after their second attack. The primary endpoint for part 2 was time to use of conventional attack treatment within 12 h of study drug administration.

RELATED REPORTS

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema

Donidalorsen reduces attacks in patients with C1 inhibitor deficiency

Garadacimab significantly reduces frequency of hereditary angioedema exacerbations

Part 1 was a safety, pharmacokinetics, and pharmacodynamics assessment which 42 (62%) of 68 participants completed. The drug was well tolerated and demonstrated evidence of rapid suppression of plasma kallikrein activity. In part 2, the time to use conventional treatment was significantly longer with sebetralstat versus placebo (at quartile 1: >12 h [95% CI 9.6 to >12] versus 8.0 h [3.8 to >12]; p=0.0010). Time to symptom relief was additionally faster with sebetralstat compared to placebo (1.6 h [1.5 to 3.0] versus 9.0 h [4.0 to 17.2]; p<0.0001). No drug-related serious adverse events or discontinuations were recorded.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: angioedemabradykininhereditary angioedemakallikreinsebetralstatswelling
Previous Post

Recommendations for opioid use in the management of chronic pain

Next Post

Dietary insoluble fiber intake may be associated with lower risk of hypertension

RelatedReports

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema
StudyGraphics

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema

April 13, 2022
Cardiology

Donidalorsen reduces attacks in patients with C1 inhibitor deficiency

March 22, 2022
Chronic Disease

Garadacimab significantly reduces frequency of hereditary angioedema exacerbations

March 16, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Infectious Disease

Development and validation of PEN-FAST clinical prediction tool for possible penicillin allergy

March 19, 2020
Next Post
Provision of medically-tailored meals linked with lower admissions and medical spending

Dietary insoluble fiber intake may be associated with lower risk of hypertension

New AAP guidelines against albuterol for bronchiolitis

RSV prefusion F protein vaccine is safe and effective in preventing RSV infection

AAP recommends disaster preparedness measures for children

BNT162b2 COVID-19 vaccine safe and efficacious in young children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Febuxostat may be effective in preventing contrast-induced acute kidney injury
  • Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer
  • United States patients receive subcutaneous fluids less frequently than intravenous fluids when compared to Canadian patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options